DESIGN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.69 USD | 0.00% |
|
+29.56% | +76.98% |
| May. 08 | Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 265M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M | Net income 2025 * | -77M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.94
x | P/E ratio 2025 * |
-3.33
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 week | +29.56% | ||
| Current month | +33.24% | ||
| 1 month | +24.73% | ||
| 3 months | +104.80% | ||
| 6 months | +129.90% | ||
| Current year | +76.98% |
1 week
3.61
5.23
1 month
3.455.23
Current year
2.255.23
1 year
1.948.47
3 years
1.9429.16
5 years
1.9450.50
10 years
1.9450.50
| Managers | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
Sean Jeffries
COO | Chief Operating Officer | 44 | 20-12-31 |
Jae B. Kim
CTO | Chief Tech/Sci/R&D Officer | 55 | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
John Schmid
BRD | Director/Board Member | 60 | 20-10-31 |
Simeon George
BRD | Director/Board Member | 46 | 20-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 4.69 | 0.00% | 1,283,321 |
| 24-05-07 | 4.69 | +28.49% | 1,786,365 |
| 24-05-06 | 3.65 | -1.88% | 136,646 |
| 24-05-03 | 3.72 | +1.92% | 173,975 |
| 24-05-02 | 3.65 | +0.83% | 148,045 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Calendar
2024-05-15
- RBC Capital Markets Healthcare Conference
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4.69
USD
Average target price
6.667
USD
Spread / Average Target
+42.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +76.98% | 265M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- DSGN Stock